Sugi Predict

Sugi Predict / Compounds / SCHEMBL236109

SCHEMBL236109

SCHEMBL236109

CC(=O)[C@@]1(n2ccc(N)nc2=O)O[C@H](CO)[C@@H](O)[C@H]1O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE3A Q14432 3/20 0.48
▸ PDE4D Q08499 1/20 0.48
▸ SLC29A1 Q99808 1/20 0.48
▸ LMNA P02545 5/20 0.48
▸ MTOR P42345 2/20 0.48
▸ THRB P10828 1/20 0.48
▸ MDM2 Q00987 1/20 0.48
▸ NCOA1 Q15788 1/20 0.48
▸ NCOA3 Q9Y6Q9 1/20 0.48
▸ POLA1 P09884 1/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ POLB P06746 1/20 0.38
▸ CACNA1F O60840 2/20 0.37
▸ ALB P02768 2/20 0.37
▸ MAPT P10636 2/20 0.37
▸ CACNA1D Q01668 2/20 0.37
▸ CACNA1S Q13698 2/20 0.37
▸ CACNA1C Q13936 2/20 0.37
▸ GMNN O75496 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phosphoric Acid SCHEMBL21465061 0.96 PDE3A (0.45) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL2991286 0.91 PDE3A (0.47) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL30514303 0.91 LMNA (0.50) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL5824290 0.90 PDE3A (0.48) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL6932187 0.90 PDE3A (0.46) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL6932196 0.90 PDE3A (0.46) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL331769 0.89 LMNA (0.49) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL26666720 0.89 LMNA (0.49) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL26109412 0.88 PDE3A (0.44) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL8716120 0.88 POLA1 (0.40) PDE3APDE4DSLC29A1LMNAMTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1247 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025038850-A1 LIPID NANOPARTICLES AND METHODS FOR SENSITIZING RESPONSE TO AN IMMUNOTHERAPY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-02-20 — — WO claimed
EP-4384635-A1 IN SITU EPITRANSCRIPTOMIC PROFILING The Broad Institute Inc. (US) 2024-06-19 — — EP claimed
WO-2024123812-A1 FUSION PROTEINS FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES SHATTUCK LABS, INC. (US) 2024-06-13 — — WO claimed
CN-117886868-A Preparation method of 5' -DMT nucleoside compound 天津奥瑞芙生物医药有限公司 2024-04-16 — — CN claimed
CN-116964220-A Multiplex analysis of RNA and DNA modifications 阿丽达生物科学公司 2023-10-27 — — CN claimed
EP-4251760-A1 MULTIPLEXED PROFILING OF RNA AND DNA MODIFICATIONS Alida Biosciences, Inc. (US) 2023-10-04 — — EP claimed
US-11773425-B2 Multiplexed profiling of RNA and DNA modifications Alida Biosciences Inc. (US) 2023-10-03 — — US claimed
WO-2022115608-A9 MULTIPLEXED PROFILING OF RNA AND DNA MODIFICATIONS ALIDA BIOSCIENCES, INC. (US) 2023-06-15 — — WO claimed
WO-2023018756-A1 IN SITU EPITRANSCRIPTOMIC PROFILING THE BROAD INSTITUTE, INC. (US) 2023-02-16 — — WO claimed
WO-2022140380-A1 METABOLOMIC SIGNATURES FOR PREDICTING, DIAGNOSING, AND PROGNOSING CHRONIC PANCREATITIS PANCREOMICS LLC (US) 2022-06-30 — — WO claimed
EP-2427470-A1 METHOD FOR THE SOLID PHASE-BASED PRODUCTION OF PHOSPHATE-BRIDGED NUCLEOSIDE CONJUGATES Universität Hamburg (DE) 2012-03-14 — — EP claimed
WO-2011113607-A1 MOLECULARLY IMPRINTED POLYMERS FOR ELIMINATING METABOLITES FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH (DE) 2011-09-22 — — WO claimed
US-20110137023-A1 METHOD FOR PRODUCING PHOSPHATE-BRIDGED NUCLEOSIDE CONJUGATES UNIVERSITAET HAMBURG (DE) 2011-06-09 — — US claimed
EP-2321330-A1 METHOD FOR PRODUCING PHOSPHATE-BRIDGED NUCLEOSIDE CONJUGATES Universität Hamburg (DE) 2011-05-18 — — EP claimed
US-20110028705-A1 METHOD FOR THE STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS COMPOUNDS UNIVERSITAET HAMBURG (DE) 2011-02-03 — — US claimed
EP-2262820-A1 METHOD FOR THE STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS COMPOUNDS Universität Hamburg (DE) 2010-12-22 — — EP claimed
WO-2010127666-A1 METHOD FOR THE SOLID PHASE-BASED PRODUCTION OF PHOSPHATE-BRIDGED NUCLEOSIDE CONJUGATES UNIVERSITÄT HAMBURG (DE) 2010-11-11 — — WO claimed
WO-2010015245-A1 METHOD FOR PRODUCING PHOSPHATE-BRIDGED NUCLEOSIDE CONJUGATES UNIVERSITÄT HAMBURG (DE) 2010-02-11 — — WO claimed
WO-2009121347-A1 METHOD FOR THE STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS COMPOUNDS UNIVERSITÄT HAMBURG (DE) 2009-10-08 — — WO claimed
CN-101237772-A P2Y for treating pulmonary diseases6Receptor agonists INSPIRE PHARMACEUTICALS INC (US) 2008-08-06 — — CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110137023-A1 METHOD FOR PRODUCING PHOSPHATE-BRIDGED NUCLEOSIDE CONJUGATES TYMP, PNP, NUDT1 PDE3A 1019/4885PDE4D 861/4885SLC29A1 19/4885
US-20110028705-A1 METHOD FOR THE STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS COMPOUNDS MTAP, PHOSPHO1, PNKP PDE3A 3040/4885PDE4D 2003/4885SLC29A1 523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.